{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:32:19Z","timestamp":1780579939094,"version":"3.54.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2023JJ30847"],"award-info":[{"award-number":["2023JJ30847"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s10637-023-01397-w","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T11:02:13Z","timestamp":1695985333000},"page":"802-807","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical characterization, treatment, and outcome of nivolumab-induced bullous pemphigoid"],"prefix":"10.1007","volume":"41","author":[{"given":"Miao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoye","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuojun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingchen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,29]]},"reference":[{"issue":"5","key":"1397_CR1","doi-asserted-by":"publisher","first-page":"e24804","DOI":"10.7759\/cureus.24804","volume":"14","author":"N Gotera","year":"2022","unstructured":"Gotera N, Weilg P, Heleno C, Ferrari-Gabilondo N (2022) A case of Bullous Pemphigoid Associated with Nivolumab Therapy. Cureus 14(5):e24804. https:\/\/doi.org\/10.7759\/cureus.24804","journal-title":"Cureus"},{"issue":"6","key":"1397_CR2","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/ijd.13984","volume":"57","author":"AT Lopez","year":"2018","unstructured":"Lopez AT, Khanna T, Antonov N, Audrey-Bayan C, Geskin L (2018) A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors. Int J Dermatol 57(6):664\u2013669. https:\/\/doi.org\/10.1111\/ijd.13984","journal-title":"Int J Dermatol"},{"key":"1397_CR3","doi-asserted-by":"publisher","unstructured":"Schmidt E, della Torre R, Borradori L (2011) Clinical features and practical diagnosis of bullous pemphigoid. Dermatol Clin. 29(3):427\u201338, viii-ix. https:\/\/doi.org\/10.1016\/j.det.2011.03.010","DOI":"10.1016\/j.det.2011.03.010"},{"issue":"3","key":"1397_CR4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jaad.2021.03.0947","volume":"86","author":"S Wongvibulsin","year":"2022","unstructured":"Wongvibulsin S, Pahalyants V, Kalinich M et al (2022) Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: a United States population-level analysis. J Am Acad Dermatol 86(3):563\u2013572. https:\/\/doi.org\/10.1016\/j.jaad.2021.03.0947","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1397_CR5","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","volume":"79","author":"J Siegel","year":"2018","unstructured":"Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione F Jr, Sznol M et al (2018) Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J Am Acad Dermatol 79(6):1081\u20131088. https:\/\/doi.org\/10.1016\/j.jaad.2018.07.008","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1397_CR6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1590\/abd1806-4841.20199007","volume":"94","author":"D Miyamoto","year":"2019","unstructured":"Miyamoto D, Santi CG, Aoki V, Maruta CW (2019) Bullous pemphigoid. An Bras Dermatol 94(2):133\u2013146. https:\/\/doi.org\/10.1590\/abd1806-4841.20199007","journal-title":"An Bras Dermatol"},{"issue":"12","key":"1397_CR7","doi-asserted-by":"publisher","first-page":"e253059","DOI":"10.1136\/bcr-2022-253059","volume":"15","author":"A Mazumder","year":"2022","unstructured":"Mazumder A, Darji K, Smith K, Guo M (2022) Two rare cases of bullous pemphigoid associated with immune checkpoint inhibitors. BMJ Case Rep 15(12):e253059. https:\/\/doi.org\/10.1136\/bcr-2022-253059","journal-title":"BMJ Case Rep"},{"issue":"10","key":"1397_CR8","doi-asserted-by":"publisher","first-page":"205427041879302","DOI":"10.1177\/2054270418793029","volume":"9","author":"T Hanley","year":"2018","unstructured":"Hanley T, Papa S, Saha M (2018) Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma. JRSM Open 9(10):2054270418793029. https:\/\/doi.org\/10.1177\/2054270418793029","journal-title":"JRSM Open"},{"issue":"5","key":"1397_CR9","doi-asserted-by":"publisher","first-page":"e13030","DOI":"10.1111\/dth.13030","volume":"32","author":"C Cuenca-Barrales","year":"2019","unstructured":"Cuenca-Barrales C, Espadafor-L\u00f3pez B, Mart\u00ednez-L\u00f3pez A, Cancela-D\u00edez B, Ruiz-Villaverde R (2019) Bullous pemphigoid in a patient treated with nivolumab. Dermatol Ther 32(5):e13030. https:\/\/doi.org\/10.1111\/dth.13030","journal-title":"Dermatol Ther"},{"issue":"1","key":"1397_CR10","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s40425-019-0669-y","volume":"7","author":"DP Hurkmans","year":"2019","unstructured":"Hurkmans DP, Basak EA, van Dijk T, Mercieca D, Schreurs MWJ, Wijkhuijs AJM et al (2019) A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. J Immunother Cancer 7(1):192. https:\/\/doi.org\/10.1186\/s40425-019-0669-y","journal-title":"J Immunother Cancer"},{"issue":"16","key":"1397_CR11","doi-asserted-by":"publisher","first-page":"8569","DOI":"10.1073\/pnas.93.16.8569","volume":"93","author":"JC Delgado","year":"1996","unstructured":"Delgado JC, Turbay D, Yunis EJ, Yunis JJ, Morton ED, Bhol K, Norman R, Alper CA, Good RA, Ahmed R (1996) A common major histocompatibility complex class II allele HLA-DQB1* 0301 is present in clinical variants of pemphigoid. Proc Natl Acad Sci U S A 93(16):8569\u20138571. https:\/\/doi.org\/10.1073\/pnas.93.16.8569","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1397_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/tan.12960","volume":"89","author":"KT Amber","year":"2017","unstructured":"Amber KT, Zikry J, Hertl M (2017) A multi-hit hypothesis of bullous pemphigoid and associated neurological disease: is HLA-DQB1*03:01, a potential link between immune privileged antigen exposure and epitope spreading? HLA 89(3):127\u2013134. https:\/\/doi.org\/10.1111\/tan.12960","journal-title":"HLA"},{"issue":"3","key":"1397_CR13","doi-asserted-by":"publisher","first-page":"e2020050","DOI":"10.5826\/dpc.1003a50","volume":"10","author":"V Di Lernia","year":"2020","unstructured":"Di Lernia V, Casanova DM, Goldust M, Ricci C (2020) Pemphigus Vulgaris and Bullous Pemphigoid: update on diagnosis and treatment. Dermatol Pract Concept 10(3):e2020050. https:\/\/doi.org\/10.5826\/dpc.1003a50","journal-title":"Dermatol Pract Concept"},{"issue":"1","key":"1397_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jdermsci.2015.01.013","volume":"78","author":"R Moriuchi","year":"2015","unstructured":"Moriuchi R, Nishie W, Ujiie H, Natsuga K, Shimizu H (2015) In vivo analysis of IgE autoantibodies in bullous pemphigoid: a study of 100 cases. J Dermatol Sci 78(1):21\u201325. https:\/\/doi.org\/10.1016\/j.jdermsci.2015.01.013","journal-title":"J Dermatol Sci"},{"key":"1397_CR15","doi-asserted-by":"publisher","unstructured":"Boch K, Hammers CM, Goletz S, Kamaguchi M, Ludwig RJ, Schneider SW, Zillikens D, Hadaschik E, Schmidt E Immunoglobulin M pemphigoid. J Am Acad Dermatol. 202;85(6):1486\u20131492. https:\/\/doi.org\/10.1016\/j.jaad.2021.01.017","DOI":"10.1016\/j.jaad.2021.01.017"},{"issue":"2","key":"1397_CR16","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1001\/archderm.136.2.174","volume":"136","author":"E Schmidt","year":"2000","unstructured":"Schmidt E, Obe K, Br\u00f6cker EB, Zillikens D (2000) Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 136(2):174\u2013178. https:\/\/doi.org\/10.1001\/archderm.136.2.174","journal-title":"Arch Dermatol"},{"issue":"4","key":"1397_CR17","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00418-012-0981-9","volume":"138","author":"T Krenacs","year":"2012","unstructured":"Krenacs T, Kiszner G, Stelkovics E, Balla P, Teleki I, Nemeth I et al (2012) Collagen XVII is expressed in malignant but not in benign melanocytic tumors and it can mediate antibody induced melanoma apoptosis. Histochem Cell Biol 138(4):653\u2013667. https:\/\/doi.org\/10.1007\/s00418-012-0981-9","journal-title":"Histochem Cell Biol"},{"issue":"4","key":"1397_CR18","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.jaad.2020.04.105","volume":"83","author":"SR Ellis","year":"2020","unstructured":"Ellis SR, Vierra AT, Millsop JW, Lacouture ME, Kiuru M (2020) Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features. J Am Acad Dermatol 83(4):1130\u20131143. https:\/\/doi.org\/10.1016\/j.jaad.2020.04.105","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1397_CR19","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1046\/j.1365-2133.2002.04835.x","volume":"147","author":"F Wojnarowska","year":"2002","unstructured":"Wojnarowska F, Kirtschig G, Highet AS, Venning VA, Khumalo NP (2002) British Association of Dermatologists. Guidelines for the management of bullous pemphigoid. Br J Dermatol 147(2):214\u2013221. https:\/\/doi.org\/10.1046\/j.1365-2133.2002.04835.x","journal-title":"Br J Dermatol"},{"issue":"4","key":"1397_CR20","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/bjd.13717","volume":"172","author":"H K\u00e1rp\u00e1ti","year":"2015","unstructured":"K\u00e1rp\u00e1ti H, Marinovic S, Mimouni B, Uzun D, Yayli S, Hertl S, Borradori M (2015) Management of bullous pemphigoid: the european Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol 172(4):867\u2013877. https:\/\/doi.org\/10.1111\/bjd.13717","journal-title":"Br J Dermatol"},{"issue":"3","key":"1397_CR21","doi-asserted-by":"publisher","first-page":"214","DOI":"10.4103\/ijd.IJD_321_18","volume":"65","author":"M Munera-Campos","year":"2020","unstructured":"Munera-Campos M, Plana-Pla A, Rivera N, Boada A, Ferr\u00e1ndiz C (2020) Nivolumab-Induced Bullous Pemphigoid Managed without Drug Withdrawal. Indian J Dermatol 65(3):214\u2013216. https:\/\/doi.org\/10.4103\/ijd.IJD_321_18","journal-title":"Indian J Dermatol"},{"issue":"9","key":"1397_CR22","doi-asserted-by":"publisher","first-page":"e591","DOI":"10.1111\/jdv.17321","volume":"35","author":"E Povilaityte","year":"2021","unstructured":"Povilaityte E, Gellrich FF, Beissert S, Abraham S, Meier F, G\u00fcnther C (2021) Treatment-resistant bullous pemphigoid developing during therapy with immune checkpoint inhibitors. J Eur Acad Dermatol Venereol 35(9):e591\u2013e593. https:\/\/doi.org\/10.1111\/jdv.17321","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01397-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-023-01397-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01397-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T01:07:09Z","timestamp":1700615229000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-023-01397-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,29]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1397"],"URL":"https:\/\/doi.org\/10.1007\/s10637-023-01397-w","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,29]]},"assertion":[{"value":"19 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study did not require an ethical board approval because the study was a retrospective study and did not involve sensitive personal information.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical considerations"}}]}}